Published in J Virol on November 15, 2006
Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One (2009) 1.78
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses. Nanomedicine (2015) 1.40
Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One (2011) 1.40
Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol (2008) 1.34
Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology (2008) 1.22
Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology (2007) 1.16
Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine (2009) 1.14
Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep (2012) 1.14
Virus-like particles as universal influenza vaccines. Expert Rev Vaccines (2012) 0.93
A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology (2011) 0.92
Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine (2010) 0.91
Incorporation of membrane-anchored flagellin or Escherichia coli heat-labile enterotoxin B subunit enhances the immunogenicity of rabies virus-like particles in mice and dogs. Front Microbiol (2015) 0.86
Incorporation of CD40 ligand into the envelope of pseudotyped single-cycle Simian immunodeficiency viruses enhances immunogenicity. J Virol (2008) 0.85
Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature. Drug Deliv Transl Res (2015) 0.82
Fluorescence molecular painting of enveloped viruses. Mol Biotechnol (2013) 0.81
Inactivated genotype 1 Japanese encephalitis vaccine for swine. Clin Exp Vaccine Res (2014) 0.81
Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung. Nanomedicine (Lond) (2014) 0.78
Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell (2015) 0.78
EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine. J Leukoc Biol (2011) 0.78
Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses. J Control Release (2016) 0.77
Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs. Sci Rep (2015) 0.77
Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles. Front Cell Infect Microbiol (2016) 0.76
Biomedical applications of glycosylphosphatidylinositol-anchored proteins. J Lipid Res (2016) 0.75
Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med (1992) 22.13
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
The CD40 antigen and its ligand. Annu Rev Immunol (1994) 7.26
CD40-CD40 ligand. J Leukoc Biol (2000) 6.28
Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A (1999) 5.66
Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A (2001) 5.46
Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol (1997) 5.21
Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci U S A (2006) 4.14
Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J Immunol (2001) 3.39
Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol (2001) 3.34
HIV vaccines. Annu Rev Immunol (2006) 3.31
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity (1995) 2.63
Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol (1987) 2.00
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res (2006) 1.94
Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine (2005) 1.80
Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood (1996) 1.66
Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol (2002) 1.58
A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol (1998) 1.54
Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood (1996) 1.42
Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol Res (2004) 1.42
Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol (1996) 1.39
Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med (1995) 1.37
IL-10 is critical for Th2 responses in a murine model of allergic dermatitis. J Clin Invest (2003) 1.36
Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology (1995) 1.26
Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol (2000) 1.24
Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol (1996) 1.20
Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology (2005) 1.16
A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine (2006) 1.15
Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol (2004) 1.13
Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology (2003) 1.07
Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunol Rev (1999) 1.06
Impaired T- and B-cell development in Tcl1-deficient mice. Blood (2004) 1.04
Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). Vaccine (2005) 1.01
Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology (1997) 1.00
A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother (2006) 0.99
Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology (1997) 0.99
Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol (1998) 0.97
Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. Eur J Immunol (2006) 0.96
A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol (2001) 0.95
Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol (2003) 0.92
Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies. Vaccine (1999) 0.92
GPI-anchoring of GM-CSF results in active membrane-bound and partially shed cytokine. Mol Immunol (2002) 0.91
Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine (2002) 0.90
Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res (2004) 0.90
CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse. J Immunol (2000) 0.89
Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells. J Med Virol (2002) 0.88
Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine. Vaccine (1999) 0.85
Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother (1998) 0.82
Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment. Cancer Immunol Immunother (2002) 0.80
Effect of B-cell receptor engagement on CD40-stimulated B cells. Immunology (1997) 0.79
CD40 expression and function on human dermal microvascular endothelial cells: role in cutaneous inflammation. Clin Exp Dermatol (2001) 0.78
A phase I and II trial of dose-intensified cyclophosphamide and GM-CSF in pediatric malignant brain tumors. J Pediatr Hematol Oncol (1995) 0.78
In vitro effects of recombinant human granulocyte-macrophage colony-stimulating factor (RhGM-CSF) on polymorphonuclear cell (PMN) and monocyte (MO) functional capacities in ovarian cancer patients versus human volunteers. Immunopharmacol Immunotoxicol (1997) 0.77
Identification of the haematopoietic stem cell niche and control of the niche size. Nature (2003) 18.17
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity (2009) 4.42
Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol (2010) 4.34
Gain-of-function experiments on H7N9. Science (2013) 3.67
Dissolving polymer microneedle patches for influenza vaccination. Nat Med (2010) 3.24
Original antigenic sin responses to influenza viruses. J Immunol (2009) 2.76
Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Pause on avian flu transmission research. Science (2012) 2.24
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog (2012) 2.09
Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol (2007) 2.06
Rescue of odontogenesis in Dmp1-deficient mice by targeted re-expression of DMP1 reveals roles for DMP1 in early odontogenesis and dentin apposition in vivo. Dev Biol (2006) 2.00
E11/gp38 selective expression in osteocytes: regulation by mechanical strain and role in dendrite elongation. Mol Cell Biol (2006) 1.98
The feasibility of measuring renal blood flow using transesophageal echocardiography in patients undergoing cardiac surgery. Anesth Analg (2009) 1.97
Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One (2009) 1.95
BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development (2008) 1.86
Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS One (2007) 1.82
Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A (2009) 1.82
Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One (2009) 1.78
Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J Immunol (2010) 1.74
Mechanical loading stimulates dentin matrix protein 1 (DMP1) expression in osteocytes in vivo. J Bone Miner Res (2003) 1.66
Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release (2009) 1.62
Evaluation of the formocresol versus mineral trioxide aggregate primary molar pulpotomy: a meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2006) 1.60
Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res (2008) 1.54
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS One (2011) 1.44
Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One (2010) 1.44
Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One (2009) 1.42
Influenza virus inhibits ENaC and lung fluid clearance. Am J Physiol Lung Cell Mol Physiol (2004) 1.40
Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One (2011) 1.40
Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology (2010) 1.39
Two-dimensional kinetics regulation of alphaLbeta2-ICAM-1 interaction by conformational changes of the alphaL-inserted domain. J Biol Chem (2005) 1.38
Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis (2010) 1.36
Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol (2008) 1.34
Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine (2006) 1.33
Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine (2006) 1.32
Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther (2012) 1.31
A comparison of autologous and allogenic bone marrow-derived mesenchymal stem cell transplantation in canine spinal cord injury. J Neurol Sci (2009) 1.31
Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol (2003) 1.29
Unique roles of phosphorus in endochondral bone formation and osteocyte maturation. J Bone Miner Res (2011) 1.29
Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One (2010) 1.28
Outcome of root canal obturation by warm gutta-percha versus cold lateral condensation: a meta-analysis. J Endod (2006) 1.27
Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol (2006) 1.26
Structural features of paramyxovirus F protein required for fusion initiation. Biochemistry (2003) 1.26
Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol (2007) 1.25
A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine (2008) 1.24
Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis (2011) 1.24
Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology (2006) 1.23
Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology (2008) 1.22
Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A (2010) 1.22
Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol (2010) 1.22
Nanotoxicity assessment of quantum dots: from cellular to primate studies. Chem Soc Rev (2013) 1.22
Inhibition of influenza infection by glutathione. Free Radic Biol Med (2003) 1.20
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol (2009) 1.20
Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation. J Virol (2003) 1.20
TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proc Natl Acad Sci U S A (2002) 1.19
A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci U S A (2004) 1.18
Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J Clin Invest (2007) 1.17
Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother (2005) 1.17
Palmitoylation of the murine leukemia virus envelope protein is critical for lipid raft association and surface expression. J Virol (2002) 1.16
Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology (2007) 1.16
Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology (2005) 1.16
Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine (2009) 1.16